<strong>Research Status of the Drugs Uesed in the Treatment of Affective Disorders Diseases</strong>

Abstract

Abstract:Affective disorders including depression (also known as unipolar depression) and bipolar disorder (unipolar depression)，are the most common psychiatric disorders, which have high incidence ratio, high recurrence ratio, and is harmful to the society. Clinically, anti-unipolar depression drugs are mainly serotonin-specific reuptake inhibitors (SSRIs), fluoxetine as represented, and serotonin/norepinephrine dual reuptake inhibitor (SNRIs), duloxetine as represented. And lithium salts (Li⁺), valproate sodium, and carbamazepine are the three classical anti-bipolar drugs. At present, researches concerning these drugs propose following major mechanisms: ①The expression of cytosolic phospholipase A2 (cPLA₂), extracellular-signal regulated kinases (ERK) and c-Fos and FosB is increased by SSRIs; ②Chronic administration of Fluoxetine could induce 5-HT_2Breceptor pre-mRNA editing, with the help of adenosine deaminase (ADAR2) activity; ③Lithium carbonate, carbamazepine, valproate sodium could upregulate the mRNA and protein of cPLA_2aand induce alkalinization of cell. But the accurate pharmacological mechanisms of these drugs have not been fully elucidated and are needed to be further investigated.

Key words:depression,serotonin-specific reuptake inhibitors (SSRIs),lithium carbonate,carbamazepine,valproate sodium,cytosolic phospholipase A₂(cPLA₂),adenosine deaminase (ADAR₂),intracellular alkalinization

CLC Number:

XUE Zhan-xia, PENG Liang.Research Status of the Drugs Uesed in the Treatment of Affective Disorders Diseases[J]. ACTA NEUROPHARMACOLOGICA, 2011, 1(3): 55-64.

References

1 Joan Kaufman，Andres Martin，Robert A King，et al. Are child-，adolescent-，and adult-onset depression one and the same disorder? [J]. Biol Psychiatry，2001，49(12): 980-1001
2 Charles B.Nemeroff.The burden of severe depression: a review of diagnostic challenges and treatment alternatives [J].，2007，41(3-4): 189-206J Psychiatr Res
3 Chad E.Beyer，Thomas I.F.H.Cremers. Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? [J]. Eur J Pharmacol，，580(3): 350-3542008
4 Papakostas George I，Cooper-Kazaz Rena，Appelhof Bente C，et al.Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies [J].，2009，24(1): 19-25Int Clin Psychopharmacol
5 Lyndal Bond，John W.Toumbourou，Lyndal Thomas，et al. Individual，family，school，and community risk and protective factors for depressive symptoms in adolescents: a comparison of risk profiles for substance use and depressive symptoms [J]. Prev Sci，，6(2): 73-882005
6 Susan E.Ramsley.Unipolar or bipolar depression? Improving diagnostic confidence with the adult patient [J].，2007，19(4): 172-178J Am Acad Nurse Pract
7 Paul J Goodnick. Anticonvulsants in the treatment of bipolar mania [J]. Expert Opin Pharmacother，2006，7(4): 401–410
8 LiBaoman B，Zhang Shiquen，Zhang Hongyan，et al. Fluoxetine-mediated 5-HT_2Breceptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation [J]. Psychopharmacology (Berl)，，201(3): 443-4582008
9 Li Baoman，Zhang Shiquen，Li Min，et al. Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT_2B-induced，transactivation-mediated ERK_1/2phosphorylation [J]. Psychopharmacology (Berl)，，207(1): 1-122009
10 Li B，Zhang S，Li M，et al. Serotonin increases ERK_1/2phosphorylation in astrocytes by stimulation of 5-HT_2Band 5-HT_2Creceptors [J]. Neurochem Int，2010，57(4): 432-439inhiquenaoman
11 Ong WY，Farooqui T，Farooqui AA.Involvement of cytosolic phospholipase A(2)，calcium independent phospholipase A(2) and plasmalogen selective phospholipase A(2) in neurodegenerative and neuropsychiatric conditions [J].，2010，17(25): 2746-2763Curr Med Chem
12 Mikhail Strokin，Marina Sergeeva，Georg Reiser.Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A₂and is differently regulated by cyclic AMP and Ca²⁺[J].，2003，139(5): 1014-1022Br J Pharmacol
13 Rao JS，Ertley RN，Lee HJ，et al.Chronic fluoxetine upregulates activity，protein and mRNA levels of cytosolic phospholipase A₂in rat frontal cortex [J].，2006，(6): 13-20Pharmacogenomics J
14 MeyerJeffrey H，Goulding VerdellS，Wilson AlanA，et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment [J]. Psychopharmacology (Berl)，，163(1): 102-1052002
15 Natalie L Rasgon，Heather A Kenna，Cheri Geist，et al. Cerebral metabolic patterns in untreated postmenopausal women with major depressive disorder [J]. Psychiatry Res，，164(1): 77-802008
16 Tim A Kimbrell，Terence A Ketter，Mark S George，et al. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression [J]. Biol Psychiatry，，51(3): 237-2522002
17 Nobler MS，Pelton GH，Sackeim HA.Cerebral blood flow and metabolism in late-life depression and dementia [J].，1999，12(3): 118-127J Geriatr Psychiatry Neurol
18 Zhang Shiquen，Li Baoman，Lovatt Ditte，et al. 5-HT_2Breceptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors [J]. Neuron Glia Biol，2010，6(2): 113-125
19 Joel Bockaert，Sylvie Claeysen，Carine Bécamel，et al. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure，signaling，and roles in synaptic modulation [J]. Cell Tissue Res，，326(2): 553-5722006
20 Porter RH，Benwell KR，Lamb H，et al. Functional characterization of agonists at recombinant human 5-HT_2A，5-HT_2Band 5-HT_2Creceptors in CHO-K1 cells [J]. Br J Pharmacol,1999, 128(1): 13-20
21 Chen Ye，Peng Liang，Zhang Xiaohu，et al. Further evidence that fluoxetine interacts with a 5-HT_2Creceptor in glial cells [J]. Brain Res Bull，，38(2): 153-1591995
22 Zhang JJ，Okutani F，Inoue S，et al. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway leading to cyclic AMP response element-binding protein phosphorylation is required for the long-term facilitation process of aversive olfactory learning in young rats [J]. Neuroscience，2003，121(1): 9-16
23 Gilles Mercier，Anna Maria Lennon，Benjamin Renouf，et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes [J]. J Mol Neurosci，2004，24(2): 207-216
24 Gruda MC，Kovary K，Metz R，et al. Regulation of Fra-1 and Fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation in vitro by MAP kinase affects DNA binding activity [J]. Oncogene，，9(9): 2537-25471994
25 Peng Liang，Li Baoman，Du Ting，et al. Astrocytic transactivation by alpha_2A-adrenergic and 5-HT_2Bserotonergic signaling [J].Neurochem Int，，57(4): 421-4312010
26 Milde-Langosch K.The Fos family of transcription factors and their role in tumourigenesis [J].，2005，41(16): 2449-2461Eur J Cancer
27 Antonia S.New，Monte S.Buchsbaum，Erin A.Hazlett，et al. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression [J]. Psychopharmacology (Berl)，，176(3-4): 451-4582004
28 Bohm SK，Grady EF，Bunnett NW. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors [J]. Biochem J，1997，322 ( Pt 1): 1-18
29 Pan Ling，Eugenia V. Gurevich，Vsevolod V. Gurevich. The nature of the arrestin x receptor complex determines the ultimate fate of the internalized receptor [J]. J Biol Chem，2003，278(13): 11623-11632
30 Roth BL，Willins DL，Kroeze WK. G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse [J]. Drug Alcohol Depend，1998，51(1-2): 73-85
31 Marion Hogg，Simona Paro，Liam P Keegan，et al.RNA editing by mammalian ADARs [J].，2011，73: 87-120Adv Genet
32 Wulf Paschen，John C. Hedreen，Christopher A.Ross. RNA editing of the glutamate receptor subunits GluR2 and GluR6 in human brain tissue [J]. J Neurochem，1994，63(5): 1596-1602
33 Colleen M.Burns，Hsin Chu，Susan M. Rueter，et al.Regulation of serotonin-2C receptor G-protein coupling by RNA editing [J]. Nature，1997，387(6630): 303-308
34 Michael T.Englander，Stephanie C.Dulawa，Punita Bhansali，et al. How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing [J]. J Neurosci，2005，25(3): 648-651
35 Li Baoman，Zhang Shiquen，Zhang Hongyan，et al.Fluoxetine affects GluK2 editing，glutamate-evoked Ca²⁺influx and extracellular signal-regulated kinase phosphorylation in mouse astrocytes [J].，2011，36(5): 322-338J Psychiatry Neurosci
36 Michael C.J.Chang，Eric Grange，Olivier Rabin，et al. Lithium decreases turnover of arachidonate in several brain phospholipids [J]. Neurosci Lett，1996，220(3): 171-174
37 Michael C.J.Chang，Miguel A.Contreras，Thad A.Rosenberger，et al. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers [J]. J Neurochem，2001，77(3): 796-803
38 Richard P. Bazinet，Jaqadeesh S. Rao，Lisa Chang，et al. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder [J]. Biol Psychiatry，2006，59(5): 401-407
39 Weerasinghe GR，Rapoport SI，Bosetti F. The effect of chronic lithium on arachidonic acid release and metabolism in rat brain does not involve secretory phospholipase A2 or lipoxygenase/cytochrome P450 pathways [J]. Brain Res Bull，2004，63(6): 485-489
40 Sandra Ghelardoni，York A Tomita，Jane M Bell，et al. Chronic carbamazepine selectively downregulates cytosolic phospholipase A₂expression and cyclooxygenase activity in rat brain [J]. Biol Psychiatry，2004，56(4): 248-254
41 Richard P. Bazinet，Jagadeesh S. Rao，Lisa Chang，et al. Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat [J]. Psychopharmacology (Berl)，，182(1): 180-1852005
42 Li Baoman，Gu Li，Zhang Hongyan，et al.Up-regulation of cPLA(2) gene expression in astrocytes by all three conventional anti-bipolar drugs is drug-specific and enzyme-specific [J].，2007，194(3): 333-345Psychopharmacology (Berl)
43 Harwood AJ. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited [J]. Mol Psychiatry，2005，10(1): 117–126
44 John R. Atack. Inositol monophosphatase inhibitors––lithium mimetics? [J]. Med Res Rev，1997，17(2): 215–224
45 Dietrich van Calker, Robert H Belmaker. The high affinity inositol transport system––implications for the pathophysiology and treatment of bipolar disorder [J]. Bipolar Disord，2000，2(2): 102–107
46 Inoue Kiyoshi，Shimada Shoichi，Minami Yuki，et al. Cellular localization of Na⁺/MYO-inositol co-transporter mRNA in the rat brain [J]. Neuroreport，，7(6): 1195-11981996
47 H. Moo. Kwon，Atsushi Yamauchi，Shinichi Uchida，et al. Cloning of the cDNa for a Na⁺/myo-inositol cotransporter，a hypertonicity stress protein [J]. J Biol Chem，，267(9): 6297-63011992
48 Beate Lubrich，Olivia Spleiss，Peter-J Gebicke-Haerter，et al. Differential expression，activity and regulation of the sodium/myo-inositol cotransporter in astrocyte cultures from different regions of the rat brain [J]. Neuropharmacology，，39(4): 680-6902000
49 Marc Uldry，Mark Ibberson，Jean-Daniel Horisberger，et al. Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain [J]. Embo J，2001，20(16): 4467-4477
50 Sproule B. Lithium in bipolar disorder: can drug concentrations predict therapeutic effect? [J]. Clin Pharmacokinet，2002，41(9): 639-660
51 Song Dan，Du Ting，Li Baoman，et al.Astrocytic alkalinization by therapeutically relevant lithium concentrations: implications for myo-inositol depletion [J].，2008，200(2): 187-195Psychopharmacology (Berl)
52 Jair C Soares，Fernando Boada，Steve Spencer，et al. Brain lithium concentrations in bipolar disorder patients: preliminary (7)Li magnetic resonance studies at 3 T [J]. Biol Psychiatry，2001，49(5): 437-443
53 Constance Moore，Christina M. Demopulos，Michael E. Henry，et al. Brain-to-serum lithium ratio and age: an in vivo magnetic resonance spectroscopy study [J]. Am J Psychiatry，2002，159(7): 1240-1242
54 Wraae O，Hillman H，Round E. The uptake of low concentrations of lithium ions into rat cerebral cortex slices and its dependence on cations [J]. J Neurochem，1976，26: 835-843
55 Alan G Mallinger，Ellen Frank，Michael E Thase，et al. Low rate of membrane lithium transport during treatment correlates with outcome of maintenance pharmacotherapy in bipolar disorder [J]. Neuropsychopharmacology，1997，16(5): 325-332
56 Philip B.Dunham，Scott J.Kelley，Paul J.Logue，et al.Na⁺-inhibitory sites of the Na⁺/H⁺exchanger are Li⁺substrate sites [J].，2005，289(2): C277-282Am J Physiol Cell Physiol
57 Yuji Furutani，Takeshi Murata，Hideki Kandori.Sodium or lithium ion-binding-induced structural changes in the K-ring of V-ATPase from Enterococcus hirae revealed by ATR-FTIR spectroscopy [J].，2011，133(9):2860-2863J Am Chem Soc
58 Mitchell Chesler. Regulation and modulation of pH in the brain [J]. Physiol Rev，2003，83(4): 1183-1221
59 Leif Hertz，Ye Chen，Maria Spatz . Involvement of non-neuronal brain cells in AVP-mediated regulation of water space at the cellular，organ，and whole-body level [J]. J Neurosci Res，2000，62(4): 480-490
60 Christine R. Rose，Stephen G. Waxman，Bruce R. Ransom. Effects of glucose deprivation，chemical hypoxia，and simulated ischemia on Na⁺homeostasis in rat spinal cord astrocytes [J]. J Neurosci，1998，18(10): 3554-3562
61 Davis BA，Hogan EM，Boron WF. Activation of Na⁺-H⁺exchange by intracellular lithium in barnacle muscle fibers [J]. Am J Physiol，1992，263(1 Pt 1): C246-C256
62 Kobayashi Y，Pang T，Iwamoto T，et al. Lithium activates mammalian Na⁺/H⁺exchangers: isoform specificity and inhibition by genistein [J]. Pflugers Arch，2000，439(4): 455-462
63 Jose A.Bitran，William Z.Potter，Husseini K.Manji，et al. Chronic Li⁺attenuates agonist- and phorbol ester-mediated Na⁺/H⁺antiporter activity in HL-60 cells [J]. Eur J Pharmacol，1990，188(4-5): 193-202
64 Emily R. Slepkov，Jan K.Rainey，Brian D.Sykes，et al.Structural and functional analysis of the Na⁺/H⁺exchanger [J].，2007，401(3): 623-633Biochem J
65 Chen Shuai，Carol Mackintosh.Differential regulation of NHE1 phosphorylation and glucose uptake by inhibitors of the ERK pathway and p90RSK in 3T3-L1 adipocytes [J].，2009，21(12): 1984-1993Cell Signal
66 Wolfgang Walz，Leif Hertz. Acute and chronic effects of lithium in therapeutically relevant concentrations on potassium uptake into astrocytes [J]. Psychopharmacology (Berl)，1982，78(4): 309-313
67 Chuang De-Maw，Wang Zhifei，Chiu Chi-Tso.GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke [J].，2011，4: 15Front Mol Neurosci
68 Xia Yan，Wang ChengZ，Liu Jie，et al.Lithium protection of phencyclidine-induced neurotoxicity in developing brain: the role of phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling pathways [J].，2008，326(3): 838-848J Pharmacol Exp Ther
69 Eric E Morgan，Margaret P Chandler，Martin E Young，et al.Dissociation between gene and protein expression of metabolic enzymes in a rodent model of heart failure [J]. Eur J Heart Fail，，8(7): 687-6932006
70 Youn-Bae Kim，Byung Ho Yang，Zhang Gen Piao，et al.Expression of Na⁺/HCO3^-cotransporter and its role in pH regulation in mouse parotid acinar cells [J].Biochem Biophys Res Commun，2003，304(4): 593-598
71 Hae Jeong Park，Ira Rajbhandari，Han Soo Yang，et al. Neuronal expression of sodium/bicarbonate cotransporter NBCn1(SLC4A7) and its response to chronic metabolic acidosis [J]. Am J Physiol Cell Physiol，2003，298(5): C1018-C1028
Marina Wolfson，Yuli Bersudsky，Evgeny Zinger，et al. Chronic treatment of human astrocytoma cells with lithium，carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations [J]. Brain Res， 2000，855(1): 158-161

[1]	XIE bin, HUANG Zhi-yuan, LIN Duo-duo, YANG Fu-long, XIE Yi-bin.Effect of Acupuncture Combined with Medicine on Depressive Symptoms of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 5-8.
[2]	MO Cui-ying, LUO Guo-ping.Influence of Nimergoline Combined with Trasylin and Psychotherapy for Depression in Patients with Post-stroke Depression[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(2): 7-10.
[3]	FU Zhi-jiang1，GAO Yun2，ZHANG Wei3，LIU Zong-chao1，4，ZHANG Hua-wen4，LIU Shi-gui1，HUANG Chen-yi1，GAO Yin5，GAO Hai-ming1.Effects and Mechanisms of Depression on Bone Fracture Healing in Rats[J]. Acta Neuropharmacologica, 2018, 8(6): 1-8.
[4]	FU Zhi-jiang1，LIU Yong1，GAO Yin1，ZHANG Wei2，GAO Yun2，LIU Zong-chao1*.Effects and Mechanisms of Depression on Bone Fracture Healing in Rats[J]. Acta Neuropharmacologica, 2018, 8(4): 5-6.
[5]	LIANG Jian-hui1,2*, LIANG hui2, CHENG tao1, LIU Xiao-yan1, Simon M.Y.Lee3, TANG Ben-qin3, WANG Xiu-fen3, CHEN Feng4,Andrew J. Lawrence4.Comorbidity of Anxiety and Depression Induced by Liang’s Contextual-Stress Box in Mice[J]. Acta Neuropharmacologica, 2018, 8(4): 44-45.
[6]	ZAN Gui-ying，SUN Xiang，LI Qing-lin，LIU Jing-gen.Research Progress of the Role and Underlying Mechanism of Dynorphin/κ Opioid Receptor in the Development of Depression[J]. Acta Neuropharmacologica, 2018, 8(1): 54-64.
[7]	LIANG Hui，CHENG Tao，LIANG Jian-hui.Progress in the Comorbidity of Depression and Anxiety[J]. Acta Neuropharmacologica, 2017, 7(6): 30-35.
[8]	ZHANG Kuo，YANG Jing-yu，WU Chun-fu.Progress on Pathophysiology and Animal Models of Depression[J]. Acta Neuropharmacologica, 2017, 7(4): 8-16.
[9]	REN Qian,WANG Zhen-zhen,CHEN Nai-hong.Regulation of Neuroplasticity by MicroRNA in Depression Disorder[J]. Acta Neuropharmacologica, 2017, 7(3): 12-20.
[10]	DU Guan-tao， LIN Jing-ran,LIU Guang-jun， HONG Hao.Research Progress on the Correlation Between Alzheimer’s Disease and Depression[J]. Acta Neuropharmacologica, 2016, 6(6): 40-44.
[11]	CAO Li-hua，BAI Ming，FANG Xiao-yan，WANG Can，MIAO Ming-san.Analysis of Animal Models of Depression Based on Clinical Symptoms[J]. Acta Neuropharmacologica, 2016, 6(4): 19-23.
[12]	ZHANG Xiao-ling，WANG Zhen-zhen，WEN Lu，SHAO Qian-hang，CHEN Nai-hong.The Relationship between Cytokines and Depression[J]. Acta Neuropharmacologica, 2016, 6(4): 31-36.
[13]	WANG Sha-sha，ZHANG Zhao，ZHANG Mei-jin，HU Jin-feng，CHEN Nai-hong.Advances of Nrf 2/ARE Signaling Pathway in the Major Depression Disorder[J]. Acta Neuropharmacologica, 2016, 6(3): 32-37.
[14]	HE Hai-ran，XUE Zhan-xia.Research Progress in the Pathogenesis of Depression[J]. Acta Neuropharmacologica, 2016, 6(2): 20-25.
[15]	JIANG Xiang-yun，SHANG Chao，LI Lei，SUN Shu-zheng，LI Yun-feng，WANG Heng-lin.Allopregnanolone as a New Therapeutic Target for Depression and Anxiety[J]. Acta Neuropharmacologica, 2016, 6(2): 26-30.

Research Status of the Drugs Uesed in the Treatment of Affective Disorders Diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics